Invesco Ltd. Purchases 2,175 Shares of Inogen Inc (NASDAQ:INGN)

Invesco Ltd. increased its position in shares of Inogen Inc (NASDAQ:INGN) by 36.2% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 8,179 shares of the medical technology company’s stock after buying an additional 2,175 shares during the period. Invesco Ltd.’s holdings in Inogen were worth $546,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Advisor Group Inc. raised its stake in Inogen by 71.4% during the 2nd quarter. Advisor Group Inc. now owns 461 shares of the medical technology company’s stock valued at $31,000 after purchasing an additional 192 shares during the last quarter. TRUE Private Wealth Advisors acquired a new position in Inogen during the 2nd quarter valued at $66,000. Steward Partners Investment Advisory LLC acquired a new position in Inogen during the 2nd quarter valued at $119,000. Fox Run Management L.L.C. acquired a new position in Inogen during the 2nd quarter valued at $226,000. Finally, Oppenheimer Asset Management Inc. raised its stake in Inogen by 2,688.5% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 3,402 shares of the medical technology company’s stock valued at $227,000 after purchasing an additional 3,280 shares during the last quarter.

In other Inogen news, Director Heath Lukatch acquired 2,000 shares of the company’s stock in a transaction dated Thursday, August 15th. The stock was bought at an average price of $43.01 per share, for a total transaction of $86,020.00. Following the purchase, the director now owns 5,481 shares in the company, valued at approximately $235,737.81. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Loren L. Mcfarland acquired 1,000 shares of the company’s stock in a transaction dated Wednesday, September 4th. The stock was acquired at an average price of $42.93 per share, with a total value of $42,930.00. Following the purchase, the director now owns 4,481 shares in the company, valued at approximately $192,369.33. The disclosure for this purchase can be found here. Corporate insiders own 4.54% of the company’s stock.

Several research firms recently commented on INGN. ValuEngine upgraded shares of Inogen from a “sell” rating to a “hold” rating in a research note on Wednesday, October 2nd. Piper Jaffray Companies cut their target price on shares of Inogen from $140.00 to $80.00 and set an “overweight” rating for the company in a research note on Wednesday, August 7th. Needham & Company LLC cut shares of Inogen from a “buy” rating to a “hold” rating in a research note on Wednesday, August 7th. BidaskClub upgraded shares of Inogen from a “strong sell” rating to a “sell” rating in a research note on Thursday. Finally, JPMorgan Chase & Co. cut shares of Inogen from a “neutral” rating to an “underweight” rating and set a $72.00 target price for the company. in a research note on Wednesday, July 3rd. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and one has given a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $82.17.

NASDAQ:INGN opened at $51.64 on Friday. Inogen Inc has a one year low of $41.19 and a one year high of $204.30. The stock has a market cap of $1.14 billion, a P/E ratio of 27.96, a PEG ratio of 4.31 and a beta of 1.51. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.35 and a quick ratio of 6.82. The company has a fifty day moving average price of $47.76 and a 200 day moving average price of $61.31.

Inogen (NASDAQ:INGN) last announced its quarterly earnings data on Wednesday, August 7th. The medical technology company reported $0.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). Inogen had a net margin of 11.24% and a return on equity of 13.34%. The business had revenue of $101.10 million during the quarter, compared to analyst estimates of $106.88 million. During the same quarter in the prior year, the company posted $0.65 EPS. The company’s quarterly revenue was up 3.9% compared to the same quarter last year. As a group, equities research analysts anticipate that Inogen Inc will post 1.09 EPS for the current year.

Inogen Company Profile

Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Further Reading: What is Call Option Volume?

Want to see what other hedge funds are holding INGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inogen Inc (NASDAQ:INGN).

Institutional Ownership by Quarter for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.